Affiliation:
1. United Hospital with Outpatient Department Managing Affairs of the President of the Russian Federation
Abstract
This review article considers the possibilities of combined antiviral therapy in the treatment of patients with COVID-19, based on the analysis of the mechanism of action of known antiviral drugs in the framework of the medical hypothesis. The potential effectiveness of the joint use of viral RNA polymerase inhibitors and a fusion inhibitor in this pathology is discussed. The review discusses the main representatives of these groups of drugs – ribavirin, riamilovir, umifenovir, favipiravir. The efficacy and safety profile of these drugs was analyzed, including the experience of their use in clinical trials conducted during the COVID-19 pandemic, as well as earlier work performed during the SARS and MERS epidemics.
Publisher
Central Research Institute for Epidemiology
Subject
Infectious Diseases,Virology,General Medicine
Reference47 articles.
1. Temporary methodical recommendations prevention, diagnostics and treatment of new coronaviral infection (COVID-19). Version 6 (28.04.2020). http://static-1.rosminzdrav.ru/system/attachments/ attaches/000/050/116/original/28042020_%D0%9CR_ COVID-19_v6.pdf (in Russian)
2. Fan H.H., Wang L.Q., Liu W.L., An X.P., Liu Z.D., He X.Q., et al. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model. Chin. Med. J. (Engl.). 2020; 133(9): 1051-6. DOI: http://doi.org/10.1097/CM9.0000000000000797
3. Hung I.F., Lung K.C., Tso E.Y., Liu R., Chung T.W., Chu M.Y., et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395(10238): 1695-704. DOI: http://doi.org/10.1016/S0140- 6736(20)31042-4
4. Grein J., Ohmagari N., Shin D., Diaz G., Asperges E., Castagna A., et al. Compassionate use of Remdesivir for patients with severe Covid-19. N. Engl. J. Med. 2020; 382(24): 2327-36. DOI: http:// doi.org/10.1056/NEJMoa2007016
5. Leyssen P., De Clercq E., Neyts J. The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Mol. Pharmacol. 2006; 69(4): 1461-7. DOI: http://doi.org/10.1124/ mol.105.020057
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献